

Print Date: 6/26/20

Title:	OMB 0920-1215 Awardee Lead Profile Assessment (ALPA)
Project Id:	0900f3eb81b58ce0
Accession #:	NCEH-LPPEHTB-5/27/20-58ce0
Project Contact:	Ruckart_Perri A. (afp4)
Organization:	NCEH/ATSDR/DEHSP/LPPEHTB
Status:	Pending Clearance
Intended Use:	Project Determination
Estimated Start Date:	02/01/2021
Estimated Completion Date:	01/31/2024
CDC/ATSDR HRPO/IRB Protocol #:	
OMB Control #:	

Determinations

Determination	Justification	Completed	Entered By & Role
HSC: Does NOT Require HRPO Review	Not Research / Other 45 CFR 46.102(I) Program Evaluation Quality Assurance / Improvement	6/26/20	Davis_Stephanie I. (sgd8) CIO HSC

PRA:	6/26/20	Davis_Stephanie I. (sgd8) CIO OMB / PRA
PRA Applies		

Description & Funding

Description

Description:

Objective:

Priority:	Standard
Date Needed:	06/05/2020
Determination Start Date:	05/28/20

This is a revision request of a currently approved OMB protocol #0920-1215 (Expiration Date 02/28/2021). The Awardee Lead Profile Assessment (ALPA) data collection instrument will be used to: 1) identify common characteristics of funded childhood lead poisoning prevention programs and 2) inform guidance, resource development, and technical assistance activities conducted by the CDC Childhood Lead Poisoning Prevention Program (CLPPP) in support of the ultimate goal, which is blood lead elimination in children. Assessment findings will be shared on the CDC CLPPP website and in response to inquiries by the public, press, and Congress. The dissemination of results will support the ability for both funded and non-funded jurisdictions to: 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts, 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities, and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead poisoning. Changes included modifying survey questions with text box answers to gateway questions with multiple choice answer options. Additionally, specific terms and phrases were revised for conciseness and clarification and questions about primary prevention and lead elimination were added to the survey.

IMS/CIO/Epi-Aid/Chemical Exposure Submission: No
IMS Activation Name: Not selected
CIO Emergency Response Name: Not selected
Epi-Aid Name: Not selected

Assessment of Chemical Exposure Name: Not selected

The purpose of this annual assessment under the cooperative agreement is to identify: 1) jurisdictional legal frameworks governing

Goals/Purpose

CDC-funded childhood lead poisoning prevention programs in the United States and 2) strategies for implementing childhood lead poisoning prevention activities in the United States.

The ALPA information collection will serve to 1) identify common characteristics of awarded childhood lead poisoning prevention programs and 2) inform guidance and resource development in support of the ultimate elimination goal. The dissemination of results obtained from this information collection will enable jurisdictions to 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts; 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities; and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead poisoning. Both funded and non-funded jurisdictions will be able to apply these principles to their childhood lead poisoning prevention programs. Findings will be shared on CDC#s CLPPP website and in response to inquiries by the public, press, and Congress.

Activities or Tasks: New Collection of Information, Data, or Biospecimens

Target Populations to be Included/Represented: Other

Tags/Keywords:

Lead Poisoning

CDC's Role:

Methods:

Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design

and data collection as a condition of any funding provided

Method Categories: Survey

> Each recipient has one project manager for lead poisoning prevention activities. Each project manager will complete the questionnaire in his or her official capacity. The ALPA questionnaire will use the Epilnfo functionality as the primary method for respondents to complete the information. The link will be sent via an invitation email by a CDC staff member to the attention of all project managers of the funded programs approximately 150 days before the end of the annual budget period. A follow-up email will be sent to the attention of all project managers approximately 130 days before the end of the annual budget period. Respondents who do not want to complete the online web questionnaire will be able to complete the Word questionnaire that will be emailed to

them by a CDC staff member.

Collection of Info, Data or Biospecimen: Via survey that will have a web-based on paper-based option

> Assessment findings will be shared on the HHLPPP CDC CLPPP website and in response to inquiries by the public, press, and Congress. The dissemination of results will support the ability for both funded and non-funded jurisdictions to: 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts, 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities, and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead

poisoning.

Expected Use of Findings/Results:

Could Individuals potentially be identified based on Information Collected?

No

Funding

Funding Type	Funding Title	Funding #	Original Budget Yr	# Years Award
CDC Cooperative Agreement	Childhood Lead Poisoning Prevention Projects, State and Local Childhood Lead Poisoning Prevention and Surveillance of Blood Lead Levels in Children	CDC-RFA-EH18- 1806	2018	3
CDC Cooperative Agreement	Lead Poisoning Prevention- Childhood Lead Poisoning Prevention	CDC-RFA-EH17- 1701PPHF17	2017	4

HSC Review

HSC Attributes

Program Evaluation Yes

Quality Assurance / Improvement Yes

Regulation and Policy

Do you anticipate this project will be submitted to the IRB office

No

Estimated number of study participants

Population - Children

Population - Minors

Population - Prisoners

Population - Pregnant Women

Population - Emancipated Minors

Suggested level of risk to subjects Do you anticipate this project will be exempt research or non-exempt research

Requested consent process waviers

Informed consent for adults

No Selection

Children capable of providing assent No Selection

Parental permission No Selection

Alteration of authorization under HIPPA Privacy

No Selection

Rule

Requested documents of informed consent

Informed consent for adults

No Selection

Children capable of providing assent No Selection

Consent process shown in an understandable language

Reading level has been estimated No Selection

Comprehension tool is provided No Selection

Short form is provided No Selection

Translation planned or performed No Selection

Certified translation / translator No Selection

Translation and back-translation to/from target

language(s)

Parental permission

No Selection

No Selection

Other method No Selection

Clinical Trial

Involves human participants No Selection

Assigned to an intervention No Selection

Evaluate the effect of the intervention No Selection

Evaluation of a health related biomedical or

behavioral outcome

No Selection

Registerable clinical trial No Selection

Other Considerations

Exception is requested to PHS informing those

bested about HIV serostatus

No Selection

Human genetic testing is planned now or in the

future

No Selection

Involves long-term storage of identfiable biological

specimens

No Selection

Involves a drug, biologic, or device

No Selection

Conducted under an Investigational New Drug exemption or Investigational Device Exemption

No Selection

Institutions & Staff

Institutions

Institutions yet to be added

Staff

Staff Member	SIQT Exp. Date	CITI Biomedical Exp. Date	CITI Social & Behavioral Exp. Date	CITI Good Clinical Practice Exp. Date	Staff Role	Email	Phone	Organization
Kelly Dyke	03/12 /2021				Data Owner	nfn8@cdc. gov	404- 498- 1215	PROGRAM SERVICES
Perri Ruckart	05/02 /2021	11/07/2020	11/20/2020		Program Official	afp4@cdc. gov	770- 488- 3808	LEAD POISONING PREVENTION AND ENVIRONMENTAL HEALTH TRACKING BRANCH
Rio Schondelmeyer	05/27 /2023				Data Use Contact	prw8@cdc. gov	404- 498- 2797	PROGRAM DEVELOPMENT, COMMUNICATIONS AND EVALUATION

Data

DMP

Proposed Data Collection Start Date: 6/1/21

Proposed Data Collection End Date: 6/28/24

Proposed Public Access Level: Public, Restricted

Restricted Details:

Data Use Type: Data Sharing Agreement

Data Use Type URL:

Data Use Contact:

Public Access Justification: de-identified data can be shared

aggregate data will be publicly available on CDC CLPPP website and additional data may be shared upon request for approved How Access Will Be Provided for Data:

purposes via data use agreement

Plans for Archival and Long Term Preservation:

Spatiality

Spatiality (Geographic Locations) yet to be added

Dataset

Dataset	Dataset	Data Publisher	Public Access	Public Access	External	Download	Type of Data	Collection	Collection End
Title	Description	/Owner	Level	Justification	Access URL	URL	Released	Start Date	Date
Dataset yet to be added									



U.S. Department of Health and Human Services

Centers for Disease Control and Prevention